app

Sorensen's PFO Closure Saga; Long QT and Pregnancy Loss; Another LAA Occluder OK'd

— Recent developments of interest in cardiovascular medicine

MedpageToday
Electrocardiogram on top and bottom of image with CardioBreak in the center.

The story of interventional cardiologist Sherman Sorensen, MD, and his , fraudulent billing, and pending malpractice lawsuits. (The Atlantic)

A cardiologist in Australia caught with is now looking at a reduced sentence of 12 months in prison. (ABC)

Singapore is offering one-time payments to people suffering serious side effects from COVID-19 vaccination. One such recipient was a 16-year-old boy who . (Bloomberg)

Several biomarkers together may be sufficient to discriminate between people with . (Journal of the American College of Cardiology)

A can help rule out non-ST-segment elevation MI (STEMI) for more people presenting with acute chest pain at emergency departments. (Circulation)

, attributed to a mutation in the KCNQ1 gene, may explain a woman's recurrent pregnancy losses. (Journal of the American Heart Association)

Approximately one in six heart failure patients in the U.S. experienced from 2004 to 2015, and money was often the root of the problem. (JACC: Heart Failure)

Stroke survivors showed better survival rates with . (Neurology)

Now, an alternative to the Watchman: FDA approved the for minimally-invasive left atrial appendage occlusion to prevent stroke in people with atrial fibrillation, Abbott announced.

The agency also cleared new software for Acutus Medical's for the mapping of complex atrial arrhythmias.

People with COVID-19 infections had more than double the risk of short-term mortality if they had a prior , according to a meta-analysis. (American Journal of Cardiology)

The proliferation of transcatheter aortic valve replacement (TAVR) has given rise to with higher risk-adjusted mortality. (Journal of the American College of Cardiology)

For TAVR candidates with pre-existing right bundle branch block, were associated with fewer cardiac rehospitalizations but no survival benefit. (Catheterization & Cardiovascular Interventions)

Did 2018's media coverage of sartan recalls lead to in the FDA adverse event reporting system database? (Circulation: Cardiovascular Quality and Outcomes)

Over nearly 20 years in Denmark, increasing recognition of had been accompanied by improved survival, even before drugs for light chain amyloidosis entered the market (JACC: CardioOncology)

Unlike the COMPLETE trial, registry data suggest no benefit to percutaneous coronary intervention in patients with STEMI. (Circulation: Cardiovascular Interventions)

Introducing Mount Sinai's app designed to make it easier for hospitals without cath labs to .

In the PARAGON-HF trial, sacubitril/valsartan (Entresto) was associated with blood pressure reductions in people who have . (European Heart Journal)

People with an indication for a pacemaker found modest reductions in systolic blood pressure after getting the Moderator device implanted for , a randomized pilot study showed. (Journal of the American Heart Association)

Choosing : go with mouse, rat, rabbit, pig, dog, or chimpanzee in the lab? (JACC: Basic to Translational Science)

  • author['full_name']

    Nicole Lou is a reporter for app, where she covers cardiology news and other developments in medicine.